• Deliverable D2.1: A review of parametric model choice used to extrapolate RCT outcomes [PDF](undefined) • Deliverable D2.2: Validation of the DICE modelling technique against existing methods and speeding up execution of the simulation engine [PDF](undefined) • Deliverable D2.3: Training modules and manuals for HTA staff, reviewers, and modelers (available on the DICE Platform)(https://dice.impact-hta.eu) • DICE platform based on Discretely Integrated Condition Event simulation to model health benefits and treatment costs during CEA modelling [LINK](https://dice.impact-hta.eu)

• Deliverable D3.1: Guidelines for cost definitions and harmonization of cost accounting methodologies for economic evaluation [PDF](undefined) • Deliverable D3.2: Database (final version) with the initial core dataset of costs and the User Manual; Final version of the Guidelines; List of standard unit costs with country values [PDF](undefined) • User Manual [PDF](undefined) • List of standard unit costs [XLSX](undefined) • Work Package Overall Results – Poster [PDF](undefined) • European Healthcare and Social Cost Database [LINK](https://www.easp.es/Impact-Hta/Default)

• Deliverable D4.1: Revising the methodological aspects applied to the identification, measurement and valuation of social costs in economic evaluations [PDF](undefined) • Deliverable D4.2: How relevant is the societal perspective in economic evaluations? Evidence from five case studies [PDF](undefined) • Deliverable D4.3: Core dataset of social costs. Creating a database on unit costs in Europe of lost work time and the value of informal and formal care time of unit costs of health services [PDF](undefined) • Work Package Overall Results [Poster PDF](undefined) • European Healthcare and Social Cost Database [LINK](https://www.easp.es/Impact-Hta/Default)

• Deliverable D5.1: Value sets for the EQ-5D-Y in Germany, Slovenia and Spain and comparison of EQ-5D-Y value sets across countries (Germany, Slovenia and Spain) [PDF](https://e1a359c7-7583-4e55-8088-a1c763d8c9d1.usrfiles.com/ugd/e1a359_98d54dc6ba7046bfa89d11f59b96dad2.pdf) • Deliverable D5.2: Comparison of EQ-5D-5L value sets from different disease areas in 2 countries (Germany and Spain) [PDF](undefined) • Work Package Overall Results – Poster [PDF](undefined) • Dataset on adult preferences toward EQ-5D-Y health states in Slovenia [PDF] (https://e1a359c7-7583-4e55-8088-a1c763d8c9d1.usrfiles.com/ugd/e1a359_17fa419d7b0f4578ba34482d6547fbb9.csv) • Dataset on adolescent preferences toward EQ-5D-Y in Slovenia [PDF] (https://e1a359c7-7583-4e55-8088-a1c763d8c9d1.usrfiles.com/ugd/e1a359_634cbf1f49534ccab6213890eee2a6c7.csv) • Dataset on adult preferences toward EQ-5D-Y health states in Germany [PDF] (https://e1a359c7-7583-4e55-8088-a1c763d8c9d1.usrfiles.com/ugd/e1a359_e357aded6fd447a38a8a2df393bdca14.xlsx) • Dataset on adolescent preferences toward EQ-5D-Yin Germany [PDF] (https://e1a359c7-7583-4e55-8088-a1c763d8c9d1.usrfiles.com/ugd/e1a359_a411ee28ae644610880c2ee13bb682ee.xls) • Dataset on preferences of diabetic patients toward EQ-5D5L health states in Germany [PDF] (https://e1a359c7-7583-4e55-8088-a1c763d8c9d1.usrfiles.com/ugd/e1a359_f9313dce40774c44a0c6f8f43d5ac544.xlsx) • Dataset on preferences of rheumatic patients toward EQ5D-5L health states in Germany [PDF] (https://e1a359c7-7583-4e55-8088-a1c763d8c9d1.usrfiles.com/ugd/e1a359_ba5c74ffc7494feca66a3a30ccbbeadc.xlsx) • Dataset on adult preferences toward EQ-5D-Y health states in Spain [PDF] (https://e1a359c7-7583-4e55-8088-a1c763d8c9d1.usrfiles.com/ugd/e1a359_4f8a8e52d4d7468e95702c67ee221838.xlsx) • Dataset on adolescent preferences toward EQ-5D-Yin Spain [PDF] (https://e1a359c7-7583-4e55-8088-a1c763d8c9d1.usrfiles.com/ugd/e1a359_66511a3016764a30ba1e660ebbb212d3.xlsx) • Dataset on preferences of diabetic patients toward EQ-5D5L health states in Spain [PDF] (https://e1a359c7-7583-4e55-8088-a1c763d8c9d1.usrfiles.com/ugd/e1a359_9e691190f161417b93b1a733469d5f3f.xlsx) • Dataset on preferences of rheumatic patients toward EQ5D-5L health states in Spain [PDF] (https://e1a359c7-7583-4e55-8088-a1c763d8c9d1.usrfiles.com/ugd/e1a359_cdecfa6e26b54e9aa32e90e68979cbb2.xlsx)

• Deliverable D6.1: Meta-epidemiological comparison of effect sizes in matched studies [PDF](undefined) • Deliverable D6.2: Recommendations on how to analyse and interpret non-randomised studies [PDF](undefined) • Dataset: Effect estimates obtained from randomised and nonrandomised studies (available December 2022)

• Deliverable D7.1: An analytical framework outlining the determinants of HTA recommendations across settings based on primary data collection and primary analysis of secondary data (available January 2023). D7.1 Executive summary [PDF](undefined) • Deliverable D7.2: Advancing knowledge and MCDA tools to assist HTA agencies in evaluating medicines on a common basis (available January 2023). D7.2 Executive summary [PDF](undefined) • Deliverable D7.3: Testing the IMPACT-HTA Value Framework in collaboration with HTA agencies: Case studies on Non-Small Cell Lung Cancer and Spinal Muscular Atrophy (available January 2023). D7.3 Executive summary [PDF](undefined) • Dataset on determinants of HTA recommendations (available January 2023) • Dataset from the 1st Delphi process to HTA stakeholders, organized into 6 parallel panels (2 rounds), about “This aspect should be considered in the evaluation of new medicines on a common basis” (2019) (available January 2023) • Dataset from the 2nd Delphi process to HTA stakeholders, organized in a single panel (2 rounds), question “This aspect should be considered in the evaluation of new medicines on a common basis” (2019) (available January 2023) • Dataset from the Web-Delphi process to INAMI stakeholders (three rounds), about “The relevance of the following value aspects for the evaluation of new medicines in this disease context is” (2020) (available January 2023) • Dataset from the Web-Delphi process to TLV stakeholders (three rounds), about “The relevance of the following value aspects for the evaluation of new medicines in this disease context is” (2020) (available January 2023)

• Deliverable D8.1: Toolkit including a list of relevant indicators to capture hospital performance variability and Toolkit to assess the transferability of evidence produced in other jurisdictions and decision-making levels [PDF](undefined) • Analysis of economic evaluation methods for hospital-based assessment – Questionnaire [excel document](undefined) • List of Indicators [PDF](undefined) • Toolkit to capture hospital performance variability [excel document](undefined) • Toolkit to assess transferability of evidence produced in other jurisdictions [https://altems.unicatt.it/altems-ricerca-a-toolkit-to-assess-the-transferability-of-evidence-produced-in-other-jurisdictions](https://altems.unicatt.it/altems-ricerca-a-toolkit-to-assess-the-transferability-of-evidence-produced-in-other-jurisdictions) • Deliverable D8.2: Toolkit of instruments to identify the clinical variability and its impact on the use of health technology [PDF](undefined) • Efficiency evaluation model for the assessment of clinical variation – Hip replacement [xslm document zip](undefined) • Efficiency evaluation model for the assessment of clinical variation – Knee replacement [xslm document zip](undefined)

• Deliverable D9.1: Algorithm for the estimation of the fiscal impact of new technologies [PDF] (undefined)and [Excel doc](undefined) • Deliverable D9.2: Evidence from pilot application from selected therapeutic areas [PDF](undefined)

• Deliverable D10.1: HTA Appraisal Framework Suitable for Rare Disease Treatments (Orphan Medicinal Products) [PDF](undefined) • Deliverable D10.2: Guidance on Use of Patient Reported Outcome Measures in HTA Appraisals of Rare Disease Treatments [PDF](undefined) • Deliverable D10.3: Guidance on Use and Implementation of Outcome-Based Managed Entry Agreements for Rare Disease Treatments [PDF](undefined) • Country vignettes: HTA appraisal/reimbursement processes for rare disease treatments in most EU and EEA Member States, Canada and New Zealand have been documented [LINK](javascript:void(0)) • Outcomes-Based Managed Entry Agreements (OBMEA) Tools to support use and implementation with a rare disease treatment: • Checklist to determine if an OBMEA is appropriate [PDF](undefined) • Template for public documentation of an OBMEA data collection agreement [WORD DOC](undefined) • Terms of reference template for a monitoring committee responsible for overseeing implementation of an OBMEA [WORD DOC](undefined) • Patient group submissions template for re-appraisal after an OBMEA [WORD DOC](undefined) • Dataset of the characteristics of AIFA registries up to 2019: Xoxi, Entela. (2021). Characteristics of AIFA registries up to 2019 [Data set]. Zenodo. [https://doi.org/10.5281/zenodo.5040265](https://doi.org/10.5281/zenodo.5040265)

• Deliverable D11.1: Systematic review of decrementally cost-effective interventions [PDF](undefined) • Deliverable D11.2: Stakeholders’ perspective: a political economy report [PDF](undefined) • Deliverable D11.3: A toolbox on candidate cost-effective technologies for HTA producers and users [PDF](undefined) • Work Package Overall Results [Poster PDF](undefined)

D12.2: An exposé of lessons learned and policy recommendations [PDF].(undefined) Summary of Project results [PDF](https://8c3e11d9-5f36-452f-abe3-c95befd6e85d.filesusr.com/ugd/f4f92f_7780fcdc4f0f48daba7431b8536d87ac.pdf)